Circulating CTRP9 attenuates myocardial ischemia/reperfusion (MI/R) injury, reverses post-MI remodeling, and promotes vasorelaxation in an endocrine fashion10–15. This evidence concerns the gene C1QTNF9 and myocardial infarction.